-->

Company Registry

712 North Inc
Profile last edited on: 1/3/2022

Personalized mitochondrial medicines
Year Founded
2016
First SBIR Year
2019
Latest SBIR Award
2019
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1814 23rd Street
San Francisco, CA 94107
   (415) 489-8995
   N/A
   www.712north.com
Multiple Locations:   
Congressional District:   12
County:   Alameda

Public Profile

712 North is a pre-clinical stage pharmaceutical company structured around development of modulators of the dynamic mitochondrial network for a range of age-related diseases to include Alzheimer's, cancer, glaucoma, and cardiovascular disease. The firm describes the approach as mitochondria biology with pharmaceutical drug development by targeting the proteases of the mitochondrial inner membrane with small molecules: proteases are highly desired drug targets with implications for many fatal disorders. Arguing that to profile the proteases in a person select ion of the right treatment - rather than reliance on a medical diagnosis - an approach that is engrained in 712 NorthÂ’s mission statement personalized mitochondrial medicines. To that end,the firm's principals have developed proprietary assays and tools for the molecular diagnosis on one hand and for the development of drugs on the other. The mechanism of action also ties the biology to a rare pediatric indication with unmet medical need. The suggestion is that principal sof the firm may be able to leverage this orphan disease as fast to market strategy.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2019 1 NIH $224,960
Discovery and Validation of OMA1 Inhibitors

Key People / Management

  Marcel V Alavi -- Founder

SBIR firms in the news

There are no news available.